PCVX Stock Overview
A clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$88.39 |
| 52 Week High | US$121.06 |
| 52 Week Low | US$48.24 |
| Beta | 1.01 |
| 11 Month Change | -21.54% |
| 3 Month Change | 11.39% |
| 1 Year Change | 80.39% |
| 33 Year Change | 318.12% |
| 5 Year Change | n/a |
| Change since IPO | 238.01% |
Recent News & Updates
Recent updates
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Sep 06We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24
Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation
May 30We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth
Dec 22Vaxcyte appoints new CBO, CMO
Oct 11Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Aug 05Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate
Jul 12Shareholder Returns
| PCVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -6.5% | -1.0% |
| 1Y | 80.4% | 14.6% | 30.3% |
Return vs Industry: PCVX exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: PCVX exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| PCVX volatility | |
|---|---|
| PCVX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PCVX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PCVX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 254 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Vaxcyte, Inc. Fundamentals Summary
| PCVX fundamental statistics | |
|---|---|
| Market cap | US$10.71b |
| Earnings (TTM) | -US$507.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.7x
P/E RatioIs PCVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$75.00m |
| Gross Profit | -US$75.00m |
| Other Expenses | US$432.65m |
| Earnings | -US$507.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PCVX perform over the long term?
See historical performance and comparison